Presentation Highlights the Efficacy of the Lead Aganocide Compound as a Potential Break-Through Treatment for Prevention of Urinary Catheter Blockage and Encrustation (UCBE) Often Leading to ...
EMERYVILLE, Calif., March 2, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide ® ...
NovaBay Pharmaceuticals, Inc., an advanced clinical-stage biopharmaceutical company developing anti-microbial products, today announced positive top-line results from its recently completed Phase 2 ...
An 85 year-old Caucasian man, affected by chronic renal failure, had been undergoing hemodialysis treatments three times a week for the previous three years. His fluid intake was controlled and he was ...
UMED Inc. (CEO Steve Myungchan Park) has drawn attention as the preclinical research results of its world-first automated intermittent bladder irrigation system, UroRinse, were published in the ...
Thirty-six patients with unsatisfactory treatment of neurogenic bowel dysfunctions (NBD) were enrolled from Spinal Units and Rehabilitation Centers in Italy. Treatment was for 3 weeks using a newly ...
LAGUNA BEACH, Calif.--(BUSINESS WIRE)--Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the first patients have been ...
European approval of next-generation ablation catheter further strengthens St. Jude Medical’s fast-growing ablation technology portfolio ST. PAUL, Minn. -- St. Jude Medical, Inc., a global medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback